Mycophenolate mofetil, an ester of mycophenolic acid, is a relatively new immunosuppressive drug that was approved by the Food and Drug Administration in 1995. The most common indication of mycophenolate mofetil is currently the prophylaxis of rejection after renal transplantation.1-3 Within the area of dermatology, successful treatment has been reported with mycophenolate mofetil in combination with high-dose prednisone therapy in 6 cases of blistering autoimmune diseases, such as pemphigus vulgaris.4,5 As high-dose steroid therapy is likely to lead to a range of severe adverse effects, such as increased susceptibility to cataract formation, development of diabetes mellitus and hypertonia, increased risk of infection, and development of Cushing disease, we attempted to evaluate the potential benefit of mycophenolate mofetil monotherapy in patients with blistering autoimmune diseases.
Grundmann-Kollmann M, Kaskel P, Leiter U, et al. Treatment of Pemphigus Vulgaris and Bullous Pemphigoid With Mycophenolate Mofetil Monotherapy. Arch Dermatol. 1999;135(6):724–725. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-6-dlt0699
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: